Rituximab Treatment for Chronic Idiopathic Axonal Polyneuropathy
Hussein Moussa1, Raja A Sawaya
1Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.
Journal of Clinical Neuromuscular Disease
|May 21, 2021
Summary
Rituximab treatment offers significant improvement for chronic idiopathic axonal polyneuropathy (CIAP). This therapy dramatically reduced symptoms like weakness and numbness in patients unresponsive to traditional treatments.
Area of Science:
- Neurology
- Immunology
Background:
- Chronic idiopathic axonal polyneuropathy (CIAP) is a progressive neurological disorder causing distal limb weakness and sensory disturbances.
- The etiology of CIAP remains unknown, and patients often do not respond to standard treatments like steroids or immunosuppressants.
Observation:
- Two cases of severe CIAP, refractory to conventional therapies, were treated with intravenous rituximab.
- Patients received rituximab as a last resort due to the severity of their debilitating symptoms.
Findings:
- Both patients experienced rapid and substantial improvement in weakness, muscle atrophy, numbness, and paresthesias within weeks of rituximab induction.
- Functional independence was significantly restored, enabling patients to resume daily activities.
Implications:
- Intravenous rituximab shows promise as an effective therapeutic option for severe chronic idiopathic axonal polyneuropathy.
- This finding suggests a potential role for B-cell depletion in managing refractory CIAP, warranting further investigation.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
274
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
274
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
299
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
299
01:20Myasthenia Gravis: Overview and Treatment
2.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.2K
01:21Rheumatic Heart Disease III: Medical Management
82
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
82